Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

The impact of early versus late palliative care referral (PCR) on healthcare utilization in pancreatic cancer patients: A single-center retrospective study.

Kriti Dhamija, Kojo-Frimpong B. Awuah, Srinishant Rajarajan et al. Jun 01, 2025 pp. 12092-12092 10.1200/jco.2025.43.16_suppl.12092

12092 Background: Pancreatic cancer is one of the most aggressive malignancies, imposing substantial physical, psychosocial, and financial stress that sig...

Performance of a targeted enzymatic methylation-based early detection test by different colorectal cancer subgroups.

Xiaojian Wu, Hong Xu, Zhijian Xu et al. Jun 01, 2025 pp. 3596-3596 10.1200/jco.2025.43.16_suppl.3596

3596 Background: Colorectal cancer (CRC) is the second most frequently diagnosed cancer in China and early detection could prevent over 90% of CRC-related...

Multiomic evaluation of TEV-56278, a PD-1-targeted attenuated IL-2 molecule, in a human ex vivo tumor model and association with immune activation with enhanced effector CD8 T cell selectivity.

Ayala Tamir, Rukiye-Nazan Eraslan, Edward O’Mara et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14506

e14506 Background: Interleukin-2 (IL-2) is critical for cancer immunity, but its therapeutic use is limited by systemic toxicity and a narrow therapeutic...

Sexual health communication and young-onset cancer (YOC): Healthcare practitioners’ attitudes and practices.

Louise Kelly, Emily Harrold, Katie O'Neill et al. Jun 01, 2025 pp. 12113-12113 10.1200/jco.2025.43.16_suppl.12113

12113 Background: Sexual health-related discussions are often challenging for Healthcare Practitioners (HCPs) and patients, making sexual health communica...

Broadening the gates: Analysis of potentially modifiable screen failures in pancreatic and biliary tract cancer trials.

Fen Saj, Felicity K. Namayanja, Mitesh Borad et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23011

e23011 Background: Eligibility criteria for clinical trials are crucial for maintaining safety and study integrity. However, they often exclude patients d...

Fc-engineered anti-CD9 antibodies with reducing platelet toxicity and efficacy against acute lymphoblastic leukemia.

Qi Zhao, Shengyu Fu, Wing-Hei Ng et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14501

e14501 Background: While CD19/CD22-targeted immunotherapies have advanced, treatment outcomes for patients with relapsed or refractory acute lymphoblastic...

In-hospital outcomes of sepsis in patients with diffuse large B-cell lymphoma: Insights from National Inpatient Sample.

Victor Adenuga, Albert Annan, Alba Caceres Munoz Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19077

e19077 Background: Per the Sepsis-3 guidelines published in 2016, sepsis was defined as a life-threatening organ dysfunction caused by a dysregulated host...

Trend of non-small cell lung cancer in young people.

Colleen Bramwell, Ummul Zakia, Dhruvkumar Gadhiya et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20509

e20509 Background: Non-small cell lung cancer (NSCLC) in young individuals is a rising concern, challenging the traditional understanding of the disease....

Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective exploratory study.

Xin Wang, Guojie Feng, Chengrui Fu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16110

e16110 Background: Therapeutic options for metastatic esophageal squamous cell carcinoma (ESCC) primarily involve immunotherapy combined with chemotherapy...

C3NIRA: Randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC).

Ana Aparicio, Rebecca Slack Tidwell, Sreyashi Basu et al. Jun 01, 2025 pp. 5008-5008 10.1200/jco.2025.43.16_suppl.5008

5008 Background: AVPC have limited therapeutic options and a dismal prognosis. Although early data indicate that adding carboplatin (Carb) to cabazitaxel...

Trends in adrenocortical cancer mortality in the US from 1999 to 2020: Regional, demographic and geographic disparities.

Junaid Anwar, Pakeeza Saif, Shafiq Ur Rahman et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23069

e23069 Background: Adrenal masses can be either benign or malignant, with adrenocortical carcinomas, being much less common than adrenal adenomas, having...

The identification of facilitators and barriers in the (pre-)emergency care pathway by patients with cancer and their caregivers.

Jason G.A. den Duijn, Leonieke W. Kranenburg, Gerrie Prins-van Gilst et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23162

e23162 Background: Up to 27% of patients with cancer receiving systemic therapy present to the emergency department (ED), often with long-standing disease...

Precision oncology in pediatric brain tumors: Real world experience from a middle income country.

Rejin Kebudi, Miray Yildirim, Ayca Iribas Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22015

e22015 Background: Despite the improvements in survival, treatment of recurrent/refractory (RR) central nervous system (CNS) tumors is challenging. Biolog...

The impact of a second primary cancer diagnosis on health-related quality of life in African American cancer survivors.

Jennifer Lynn Beebe-Dimmer, Julie Ruterbusch, Kathleen A. Cooney et al. Jun 01, 2025 pp. 11133-11133 10.1200/jco.2025.43.16_suppl.11133

11133 Background: Survival for the most common cancers has improved dramatically over the past several decades due to advances in treatment and screening...

NuGenA (Nurse Led Genetic Counselling and Awareness): A proof-of-concept to implementation of genetic counseling for HBOC in LMICs.

Asima Mukhopadhyay, Dona Chakraborty, Daity Bhattacharjee et al. Jun 01, 2025 pp. 10583-10583 10.1200/jco.2025.43.16_suppl.10583

10583 Background: Poor access to genetic testing and counselling represents a major gap in cancer care in resource-restricted-settings. Our pilot work in...

Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.

Sedat Biter, Ahmet Taner Sümbül, Serdar Karakaya et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20659

e20659 Background: ROS-1-positive non-small cell lung cancers (NSCLCs) are rare, accounting for approximately 1-2% of all NSCLCs. Lorlatinib is a potent,...

Triplet therapy for FLT3-mutated acute myeloid leukemia in Puerto Rico: A retrospective study.

William Doel Marrero-León, Hector R. Cintron-Colon, Dominic Sanchez Paredes et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18534

e18534 Background: Acute myeloid leukemia (AML) is a highly heterogeneous disease frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3)...

Efficacy and safety of surufatinib (S) plus KN046 (K) and chemotherapy in first line (1L) advanced pancreatic cancer (PC): A single-arm, phase 1b/2 trial.

Wen-Quan Wang, Lin-Hui Tang, Yu Li et al. Jun 01, 2025 pp. 4157-4157 10.1200/jco.2025.43.16_suppl.4157

4157 Background: Gemcitabine (G) and nab-paclitaxel (nP) are standard 1L regimen for patients (pts) with unresectable PC, yet the efficacy remains unsatis...

Acute circulating tumor DNA dynamics during and after infusional therapy initiation.

Briana To, Vishnu Prasath, Deloris Veney et al. Jun 01, 2025 pp. 1099-1099 10.1200/jco.2025.43.16_suppl.1099

1099 Background: For patients with advanced breast cancer, the proportion of tumor-derived DNA in circulation (‘tumor fraction’/TF) has been shown to be p...

Temporal trends of mortality due to laryngeal cancer among older adults in United States: A CDC WONDER analysis on gender, race, and geographical disparities.

Muhammad Shaheer Bin Faheem, Anam Ashfaque, Muhammad Bilal Masood Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18037

e18037 Background: Laryngeal cancer is a significant global health burden arising in supraglottic or glottic regions and accounts for 33% of head and neck...

Use of brain protein I3 (BRI3) to predict disease fate in glioblastoma.

Ifeanyichukwu Ogobuiro, Scott M. Welford, Markus Bredel Jun 01, 2025 pp. 2047-2047 10.1200/jco.2025.43.16_suppl.2047

2047 Background: Genome-wide characterization has illuminated the molecular complexity of human gliomas. Genetic alterations help predict the clinical beh...

Effect of a daily scrum at the gastrointestinal oncology ward on length of stay: A tertiary center experience.

Antoon Billiet, Wouter De Haes, Cindy Van Eembeek et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13540

e13540 Background: The disease course of oncology patients often results in repeated hospitalization and prolonged length of stay (LOS). Next to disease a...

Deep learning–powered H&E whole-slide image analysis of endothelial cells to characterize tumor vascular environment and correlate treatment outcome to immunotherapy.

Seungeun Lee, Jin Woo Oh, Soohyun Hwang et al. Jun 01, 2025 pp. 2578-2578 10.1200/jco.2025.43.16_suppl.2578

2578 Background: Beyond their vascular function, endothelial cells (ECs) regulate tumor growth through recently described angiocrine signaling, influencin...

Relevance and specificity of the French CIAN LUNG cohort for clinical research analyses in lung cancer using real-world data.

Khedidja Hedna, Aurélie Swalduz, Sylvie Van Hulst et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23314

e23314 Background: Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality worldwide. Conducting...

Comparison of cancer study enrollments between urban, rural, frontier and remote participants.

Tinotenda Sekeramayi, Shabbir Haiderbhai, Tyler Sang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13749

e13749 Background: In the United States (US), less than 5% of patients participate in cancer research studies, with community sites that serve rural parti...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page